ライフサイエンスコーパス: subtilisin

1 (4) (cathepsin G) to 7.1 x 10(5) m(-1)s(-1) (subtilisin).

2 en both enzymes, while 37% were exclusive to subtilisin.

3 s targeting the serine proteases trypsin and subtilisin.

4 degrees of hydrolysis (DH) of 3-4-5-6% with subtilisin.

5 s Pronase, proteinase K, pepsin, papain, and subtilisin.

6 ease in its susceptibility to proteolysis by subtilisin.

7 avage of alphaENaC using the serine protease subtilisin.

8 tivity (4.1 microS), and were insensitive to subtilisin.

9 Here, we show that addition of subtilisin (50 nm to 2 mum), a serine protease secreted

10 nts but not bovine chymotrypsin or bacterial subtilisin A.

11 alysis of secretions reveals the presence of subtilisin (a protease) and a 12 kDa protein, termed sib

12 PEGylation of subtilisin-A (Sub-A) was performed by attaching methoxyp

13 We therefore aimed to protect and maintain subtilisin-A enzyme activity by exploring two pharmaceut

14 The PEGylation protected subtilisin-A from autolysis at neutral pH.

15 vel not significantly different from that of subtilisin activated alphaWT (125.6 +/- 23.9).

16 C-terminal peptide that may insert into the subtilisin active site.

17 Finally, subtilisin activity acted as a Th2 adjuvant to an unrela

18 Notably, subtilisin allows reproducible near-complete digestion o

19 PCs are evolutionarily related to bacterial subtilisin and are synthesized as zymogens.

20 ental model of allergic lung inflammation to subtilisin and to determine the immunological mechanisms

21 age of the similarity of SUB1 with bacterial subtilisins and generated P. vivax SUB1 three-dimensiona

22 ophil and pancreatic elastases, cathepsin G, subtilisin, and trypsin) with a stoichiometry of inhibit

23 The propeptide domain of subtilisin BPN' functions as a molecular chaperone for i

24 ixed backbone design, we have redesigned the subtilisin BPN' propeptide structure to generate synthet

25 Finally, we demonstrate that subtilisin can be used for reporter-ion based in-depth q

26 R spectroscopy experiments were performed on subtilisin Carlsberg colyophilized with several inorgani

27 bute to accelerated catalysis by solubilized subtilisin Carlsberg upon hydration in organic solvents.

28 The enzyme subtilisin Carlsberg was surfactant-solubilized into two

29 here that phosphorylation of Tyr-53 inhibits subtilisin cleavage of the D-loop and reduces the rate o

30 alphaFM were activated to similar levels by subtilisin cleavage.

31 However, subtilisin considerably improved the coverage of missing

32 t does not inhibit serine peptidases such as subtilisin, elastase, chymotrypsin, thrombin, and plasmi

33 e present how the broad-specificity protease subtilisin enables mapping of previously hidden areas of

34 of all plasmodia and are mapped between the subtilisin-encoding genes SUB1 and SUB3 P. berghei PIMMS

35 t these epitopes can be degraded in vitro by subtilisin enzymes derived from Rothia mucilaginosa, a n

36 entity with fungal serine proteinases of the subtilisin family, indicating that AsES is synthesized a

37 ensitive disulphide bridge, unique among the subtilisin family, that likely acts as a regulator of pr

38 An engineered variant of the protease subtilisin from Bacillus amyloliquefaciens, in which the

39 Because usage of the serine protease subtilisin in the detergent industry resulted in an outb

40 ensitization followed by airway challenge to subtilisin induces prototypic allergic lung inflammation

41 carpus viz., chitinase (CHI4), Alpha-amylase/subtilisin inhibitor (IAAS) and Flavonoid 3_5 hydroxylas

42 ty for the generation of novel proteinaceous subtilisin inhibitors.

43 Notably, acute administration of subtilisin into the airways increased lung IL-5-producin

44 These data suggest that subtilisin is the maturase for tryparedoxin peroxidases

45 Serum proprotein convertase subtilisin kexin 9 (PCSK9) binds to low-density lipoprot

46 Since the discovery of proprotein convertase subtilisin kexin 9 (PCSK9) in 2003, this PC has attracte

47 viral envelope glycoprotein by the cellular subtilisin kexin isozyme 1 (SKI-1)/site 1 protease (S1P)

48 glycoprotein precursor (GPC) by the cellular subtilisin kexin isozyme 1 (SKI-1)/site 1 protease (S1P)

49 The proprotein convertase subtilisin kexin isozyme 1 (SKI-1)/site 1 protease (S1P)

50 The proprotein convertase subtilisin kexin isozyme-1 (SKI-1)/site-1 protease (S1P)

51 (dec-RRLL-cmk), inhibitors of SKI-1 (site 1; subtilisin kexin like-1) protease.

52 ndogenous inhibitor of proprotein convertase subtilisin kexin type 9 (PCSK9) activity on cell-surface

53 poprotein B (APOB), or proprotein convertase subtilisin kexin type 9 (PCSK9) genes.

54 Proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors produce incre

55 ockers, ezetimibe, and proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors, are discusse

56 Proprotein convertase subtilisin kexin type 9 (PCSK9) levels are frequently fo

57 Proprotein convertase subtilisin kexin type 9 (PCSK9) promotes the degradation

58 Levels of proprotein convertase subtilisin kexin type 9 (PCSK9) vary markedly across the

59 levels of circulating proprotein convertase subtilisin kexin type 9 (PCSK9) would increase cardiovas

60 lonal antibody against proprotein convertase subtilisin kexin type 9 (PCSK9), on Lp(a).

61 nal antibodies against proprotein convertase subtilisin kexin type 9 (PCSK9), such as evolocumab, low

62 ibody directed against proprotein convertase subtilisin kexin type 9 (PCSK9), to enable subjects at h

63 PCSK9i (proprotein convertase subtilisin kexin type 9 inhibitors) reduce low-density l

64 ol-lowering drugs, the proprotein convertase subtilisin kexin-9 inhibitors.

65 inogenesis in some solid tumors, the role of subtilisin-kexin isoenzyme-1 (SKI-1) in this context is

66 antibody that inhibits proprotein convertase subtilisin-kexin type 9 (PCSK9) and lowers low-density l

67 antibody that inhibits proprotein convertase subtilisin-kexin type 9 (PCSK9) and reduces levels of lo

68 acologic inhibitors of proprotein convertase subtilisin-kexin type 9 (PCSK9) are being evaluated in c

69 Proprotein convertase subtilisin-kexin type 9 (PCSK9) binds to the low-density

70 of drugs that inhibit proprotein convertase subtilisin-kexin type 9 (PCSK9) has been developed to tr

71 odies directed against proprotein convertase subtilisin-kexin type 9 (PCSK9) have been shown to reduc

72 rom clinical trials of proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors have led to c

73 nce of the efficacy of proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors; however, the

74 on LDL cholesterol and proprotein convertase subtilisin-kexin type 9 (PCSK9) levels were available th

75 ibits the synthesis of proprotein convertase subtilisin-kexin type 9 (PCSK9), a target for the loweri

76 antibody that inhibits proprotein convertase subtilisin-kexin type 9 (PCSK9), has been shown to reduc

77 nal antibody targeting proprotein convertase subtilisin-kexin type 9 (PCSK9), reduces levels of low-d

78 antibody that inhibits proprotein convertase subtilisin-kexin type 9 (PCSK9), significantly reduced l

79 monoclonal antibody to proprotein convertase subtilisin-kexin type 9 (PCSK9).

80 t of lipid lowering by proprotein convertase subtilisin-kexin type 9 inhibition in such patients is u

81 esterol reduction with proprotein convertase subtilisin-kexin type 9 inhibitors reduces ischemic even

82 ion variants in PCSK9 (proprotein convertase subtilisin-kexin type 9) are associated with lower lifet

83 vious trials of PCSK9 (proprotein convertase subtilisin-kexin type 9) inhibitors demonstrated reducti

84 ibody directed against proprotein convertase subtilisin-kexin type 9, is widely used in adult patient

85 s hepatic synthesis of proprotein convertase subtilisin-kexin type 9.

86 vertase site 1 protease (S1P), also known as subtilisin-kexin-isozyme 1 (SKI-1), is crucial for cell-

87 Proprotein convertase subtilisin/kexin (PCSK) enzymes convert proproteins into

88 Serum proprotein convertase subtilisin/kexin 9 (PCSK9) binds to low-density lipoprot

89 in the promoter of the proprotein convertase subtilisin/kexin 9 (PCSK9) gene that was associated with

90 efficacy and safety of proprotein convertase subtilisin/kexin 9 (PCSK9) inhibitors in secondary preve

91 Proprotein convertase subtilisin/kexin 9 (PCSK9) is a key regulator of lipid m

92 ed that >30% of plasma proprotein convertase subtilisin/kexin 9 (PCSK9) is bound to LDL, thus we pred

93 Proprotein convertase subtilisin/kexin 9 (PCSK9) is responsible for the degrad

94 dy-based inhibitors of preprotein convertase subtilisin/kexin 9 (PCSK9) produce reductions in LDL-C o

95 noclonal antibodies to proprotein convertase subtilisin/kexin 9 (PCSK9) reduce LDL cholesterol in het

96 l due to inhibition of proprotein convertase subtilisin/kexin 9 (PCSK9) reduces cardiovascular events

97 Proprotein convertase subtilisin/kexin 9 (PCSK9) regulates plasma LDL choleste

98 Proprotein convertase subtilisin/kexin 9 (PCSK9), one of the serine proteases,

99 PCSK9 (proprotein convertase subtilisin/kexin 9) inhibitors have been shown to signif

100 , apolipoprotein B, or proprotein convertase subtilisin/kexin 9.

101 The proprotein convertase subtilisin/kexin enzymes proteolytically convert immatur

102 n is unique among the proprotein convertases subtilisin/kexin in being highly expressed in human GIC.

103 educed, and intestinal proprotein convertase subtilisin/kexin type 1 (Pcsk1) expression, the gene enc

104 rare mutations in the proprotein convertase subtilisin/kexin type 1 (PCSK1) gene, has been associate

105 ulated transcript, and proprotein convertase subtilisin/kexin type 1 inhibitor.

106 olymorphisms (SNPs) in proprotein convertase subtilisin/kexin type 1 with modest effects on PC1/3 in

107 Proprotein convertase subtilisin/kexin type 2 (PCSK2) is a prohormone processi

108 ies in its convertase, proprotein convertase subtilisin/kexin type 5 (PCSK5), causing inactive GDF11

109 etween ANGPTL3, furin, proprotein convertase subtilisin/kexin type 5 (PCSK5), paired amino acid conve

110 pon hypoxia was PCSK6 (proprotein convertase subtilisin/kexin type 6).

111 l with an inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9) after acute coronary syn

112 Proprotein convertase subtilisin/kexin type 9 (PCSK9) and inducible degrader o

113 individually bind the proprotein convertase subtilisin/kexin type 9 (PCSK9) and regulate its activit

114 ntibodies that inhibit proprotein convertase subtilisin/kexin type 9 (PCSK9) are an emerging therapy

115 ction mutations of the proprotein convertase subtilisin/kexin type 9 (PCSK9) are associated with hype

116 Proprotein convertase subtilisin/kexin type 9 (PCSK9) binds LDL receptors, tar

117 Proprotein convertase subtilisin/kexin type 9 (PCSK9) binds low-density lipopr

118 Proprotein convertase subtilisin/kexin type 9 (PCSK9) binds to LDL receptors,

119 Plasma proprotein convertase subtilisin/kexin type 9 (PCSK9) binds to low-density lip

120 Proprotein convertase subtilisin/kexin type 9 (PCSK9) binds to the low-density

121 Proprotein convertase subtilisin/kexin type 9 (PCSK9) deficiency leads to lowe

122 etermine the effect of proprotein convertase subtilisin/kexin type 9 (PCSK9) deficiency on developmen

123 Proprotein convertase subtilisin/kexin type 9 (PCSK9) down-regulates surface e

124 Proprotein convertase subtilisin/kexin type 9 (PCSK9) down-regulates the low-d

125 dation mediated by the proprotein convertase subtilisin/kexin type 9 (PCSK9) has been extensively stu

126 Soluble proprotein convertase subtilisin/kexin type 9 (PCSK9) has been shown to be pre

127 Proprotein convertase subtilisin/kexin type 9 (PCSK9) increases serum LDL-chol

128 ty and efficacy of the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor evolocumab in

129 The proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor evolocumab red

130 t use of ezetimibe and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients w

131 Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors substantially

132 Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors were recently

133 include ezetimibe and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, which both r

134 l antibodies targeting proprotein convertase subtilisin/kexin type 9 (PCSK9) is a new lipid-lowering

135 The secreted protein proprotein convertase subtilisin/kexin type 9 (PCSK9) is a promising new targe

136 Proprotein convertase subtilisin/kexin type 9 (PCSK9) is an important factor i

137 Do elevated proprotein convertase subtilisin/kexin type 9 (PCSK9) levels constitute an eve

138 shown that circulating proprotein convertase subtilisin/kexin type 9 (PCSK9) levels correlate positiv

139 in receptor (LDLR) and proprotein convertase subtilisin/kexin type 9 (PCSK9) messenger ribonucleic ac

140 Proprotein convertase subtilisin/kexin type 9 (PCSK9) modulates low-density li

141 Proprotein convertase subtilisin/kexin type 9 (PCSK9) plays a key role in regu

142 Proprotein convertase subtilisin/kexin type 9 (PCSK9) plays an important role

143 Proprotein convertase subtilisin/kexin type 9 (PCSK9) posttranslationally regu

144 e the LDL-ApoB-100 and proprotein convertase subtilisin/kexin type 9 (PCSK9) production rate (PR) and

145 The proprotein convertase subtilisin/kexin type 9 (PCSK9) promotes independently o

146 Proprotein convertase subtilisin/kexin type 9 (PCSK9) regulates low density li

147 Proprotein convertase subtilisin/kexin type 9 (PCSK9) regulates serum LDL chol

148 Proprotein convertase subtilisin/kexin type 9 (PCSK9) selectively binds low-de

149 lonal antibody against proprotein convertase subtilisin/kexin type 9 (PCSK9) serine protease, demonst

150 strategies to inhibit proprotein convertase subtilisin/kexin type 9 (PCSK9) show promise as anti-hyp

151 its negative regulator proprotein convertase subtilisin/kexin type 9 (PCSK9) through the first EGF (e

152 Proprotein convertase subtilisin/kexin type 9 (PCSK9) was shown to have a mutu

153 antibodies that block proprotein convertase subtilisin/kexin type 9 (PCSK9), a circulating protein t

154 ment for repression of proprotein convertase subtilisin/kexin type 9 (PCSK9), a gene that, when repre

155 at evaluating whether proprotein convertase subtilisin/kexin type 9 (PCSK9), a key regulator of low-

156 t ENaC is regulated by proprotein convertase subtilisin/kexin type 9 (PCSK9), a protease that modulat

157 ated the expression of proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein that facilita

158 presence of exogenous proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein that reduces

159 d glucose, endothelin, proprotein convertase subtilisin/kexin type 9 (PCSK9), adhesion molecules, and

160 olipoprotein B (APOB), proprotein convertase subtilisin/kexin type 9 (PCSK9), and LDL protein recepto

161 mutations in the apoB, proprotein convertase subtilisin/kexin type 9 (PCSK9), and MTP genes result in

162 monoclonal antibody to proprotein convertase subtilisin/kexin type 9 (PCSK9), demonstrated marked red

163 ntibodies that bind to proprotein convertase subtilisin/kexin type 9 (PCSK9), lowering LDL by about 5

164 monoclonal antibody to proprotein convertase subtilisin/kexin type 9 (PCSK9), lowers plasma low-densi

165 monoclonal antibody to proprotein convertase subtilisin/kexin type 9 (PCSK9), reduced LDL cholesterol

166 C1-Like 1 (NPC1L1) and proprotein convertase subtilisin/kexin type 9 (PCSK9), respectively.

167 antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9), significantly reduced l

168 lonal antibody against proprotein convertase subtilisin/kexin type 9 (PCSK9), significantly reduced l

169 lonal antibody against proprotein convertase subtilisin/kexin type 9 (PCSK9), significantly reduced L

170 induced expression of proprotein convertase subtilisin/kexin type 9 (PCSK9), which reduces low-densi

171 l antibodies targeting proprotein convertase subtilisin/kexin type 9 (PCSK9).

172 circulating levels of proprotein convertase subtilisin/kexin type 9 (PCSK9).

173 lonal antibody against proprotein convertase subtilisin/kexin type 9 (PCSK9).

174 ications (ezetimibe or proprotein convertase subtilisin/kexin type 9 [PCSK9] inhibitors) to statin th

175 Importantly, reduced proprotein convertase subtilisin/kexin type 9 activity increases recycling of

176 g activity using human proprotein convertase subtilisin/kexin type 9 and platelet factor-4, whereas t

177 Plasma proprotein convertase subtilisin/kexin type 9 and total cholesterol increased

178 Using proprotein convertase subtilisin/kexin type 9 as a representative protein targ

179 ascular pathology in a proprotein convertase subtilisin/kexin type 9 gain-of-function atherosclerosis

180 quence variants in the proprotein convertase subtilisin/kexin type 9 gene (PCSK9) lower plasma low-de

181 The Proprotein Convertase Subtilisin/Kexin type 9 genetic score finding raises the

182 Surprisingly the Proprotein Convertase Subtilisin/Kexin type 9 genetic score, known to be direc

183 e was observed for the Proprotein Convertase Subtilisin/Kexin type 9 genetic score.

184 aryl-CoA Reductase and Proprotein Convertase Subtilisin/Kexin type 9 genetic scores should have been

185 e (the effect of these Proprotein Convertase Subtilisin/Kexin type 9 genotypes) may contribute to imp

186 ectiveness analyses of proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9i) were based on

187 The proprotein convertase subtilisin/kexin type 9 inhibitor evolocumab has been de

188 Proprotein convertase subtilisin/kexin type 9 inhibitor therapy is a treatment

189 Alirocumab, a proprotein convertase subtilisin/kexin type 9 inhibitor, lowers lipoprotein(a)

190 95% CI, 0.58-0.65) for proprotein convertase subtilisin/kexin type 9 inhibitors (P = .25).

191 Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) are a novel

192 interest in leveraging proprotein convertase subtilisin/kexin type 9 inhibitors as a therapeutic stra

193 ining lipoproteins and proprotein convertase subtilisin/kexin type 9 inhibitors hold promise in reduc

194 PCSK9i (protein convertase subtilisin/kexin type 9 inhibitors) are set to revolutio

195 nical trials involving proprotein convertase subtilisin/kexin type 9 inhibitors.

196 Proprotein convertase subtilisin/kexin type 9 is a central regulator of lipid

197 cytes, and knocks down proprotein convertase subtilisin/kexin type 9 level in mouse serum down to 20%

198 Proprotein convertase subtilisin/kexin type 9 loss-of-function decreased survi

199 Proprotein convertase subtilisin/kexin type 9 loss-of-function is associated w

200 ast to the adult host, proprotein convertase subtilisin/kexin type 9 loss-of-function is detrimental

201 Proprotein convertase subtilisin/kexin type 9 monoclonal antibodies can reduce

202 ncode gain-of-function proprotein convertase subtilisin/kexin type 9 mutants, and mice were given a s

203 erol, campesterol, and proprotein convertase subtilisin/kexin type 9 plasma concentrations and fatty

204 noclonal antibodies to proprotein convertase subtilisin/kexin type 9 published in the last 18 months

205 Inhibition of proprotein convertase subtilisin/kexin type 9 serine protease (PCSK9) resulted

206 Proprotein convertase subtilisin/kexin type 9 single-nucleotide polymorphisms,

207 ve data that targeting proprotein convertase subtilisin/kexin type 9 very effectively reduces LDL-cho

208 has identified PCSK9 (proprotein convertase subtilisin/kexin type 9) as a crucial gene in the regula

209 targeting human PCSK9 (proprotein convertase subtilisin/kexin type 9) as an alternative to anti-PCSK9

210 PCSK9 (proprotein convertase subtilisin/kexin type 9) has emerged as a novel therapeu

211 PCSK9 (proprotein convertase subtilisin/kexin type 9) has emerged as an important reg

212 er benefit from PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibition has not been establi

213 e the effect of PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibition on the risk of VTE,

214 The PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitor evolocumab reduced lo

215 y alirocumab, a PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitor.

216 suggested that PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors are safe and reduce

217 PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors reduce lipoprotein(a

218 PCSK9 (proprotein convertase subtilisin/kexin type 9) is a negative regulator of the

219 regulating the PCSK9 (proprotein convertase subtilisin/kexin type 9) levels.

220 nal antibody to PCSK9 (proprotein convertase subtilisin/kexin type 9), markedly reduces low-density l

221 ody that blocks PCSK9 (proprotein convertase subtilisin/kexin type 9), was associated with reduced ma

222 KO/APOB100, and PCSK9 (proprotein convertase subtilisin/kexin type 9)-overexpressing mice were all si

223 vector overexpressing proprotein convertase subtilisin/kexin type 9).

224 contrast, bile acids, proprotein convertase subtilisin/kexin type 9, acetate, and acetoacetate were

225 nd Septic Shock Trial, Proprotein Convertase Subtilisin/Kexin type 9, and 3-Hydroxy-3-Methylglutaryl-

226 e polymorphisms, serum proprotein convertase subtilisin/kexin type 9, and lipid profiles in patients.

227 noclonal antibodies to proprotein convertase subtilisin/kexin type 9, cholesterol ester transfer prot

228 achieved by inhibiting proprotein convertase subtilisin/kexin type 9, may decrease the systemic infla

229 Single injections of proprotein convertase subtilisin/kexin type 9-encoding recombinant adeno-assoc

230 levels of circulating proprotein convertase subtilisin/kexin type 9.

231 Proprotein convertase subtilisin/kexin type-9 (PCSK9) is a ligand of low-densi

232 Proprotein convertase subtilisin/kexin type-9 (PCSK9) is a secreted protein th

233 Proprotein convertase subtilisin/kexin type-9 (PCSK9, a hepatic LDL-receptor r

234 pharmacological PCSK9 (proprotein convertase subtilisin/kexin type-9) inhibition was not associated w

235 The archetype proprotein convertase subtilisin/kexin, FURIN, is a direct target gene of the

236 Here we show that proprotein convertase subtilisin/kexin-6 (PCSK6, also named PACE4;) cleaves an

237 Recently approved proprotein convertase subtilisin/kexin-type 9 inhibitors and mipomersen lower

238 of the family of the proprotein convertases subtilisin/kexin.

239 PCSKs (Proprotein convertase subtilisins/kexins) are a protease family with unknown f

240 acid residues corresponding to the putative subtilisin-like catalytic triad are important but not es

241 chanism and structural characterization of a subtilisin-like collagenolytic protease secreted by a de

242 Here, a novel subtilisin-like collagenolytic protease, myroicolsin, wh

243 chonia chlamydosporia belongs to a family of subtilisin-like enzymes that are involved in infection o

244 o V. cholerae in vivo IvaP bears homology to subtilisin-like enzymes, a large family of serine protea

245 Unlike many other subtilisin-like enzymes, the IvaP cleavage pattern is co

246 cture of MycP1(24-407) to 1.86 A, defining a subtilisin-like fold with a unique N-terminal extension

247 ithelial expression of proprotein convertase subtilisin-like kexin type 9, a key regulator of cholest

248 lipoprotein B-100, and proprotein convertase subtilisin-like kexin type 9.

249 olipoprotein B-100 and proprotein convertase subtilisin-like kexin type 9.

250 machinery (including propeptide precursors, subtilisin-like prohormone convertases, amidated product

251 rotein convertase 7 (PC7) is a member of the subtilisin-like proprotein convertase family, which is i

252 motes FGF23 cleavage and inactivation by the subtilisin-like proprotein convertase furin.

253 0), within the FGF23 R(176)XXR(179)/S(180)AE subtilisin-like proprotein convertase motif.

254 Subtilisin-like proprotein convertases (SPCs) are a fami

255 inactive precursor molecules by a family of subtilisin-like proprotein convertases (SPCs).

256 was found to be derived from a member of the subtilisin-like protease (subtilase) family.

257 We previously showed that a subtilisin-like protease called PfSUB1 regulates egress

258 The subtilisin-like protease P69B was identified as a substr

259 identity (<30%) to previously characterized subtilisin-like proteases, and it contains a novel domai

260 tively encoding oxylipin metabolic proteins, subtilisin-like proteases, and other antimicrobial defen

261 s are mediated respectively, by two parasite subtilisin-like proteases, PfSUB1 and PfSUB2, but the fu

262 ghei protein with structural similarities to subtilisin-like proteins.

263 E activity in seed coat epidermal cells, the subtilisin-like Ser protease SBT1.7, acts on different P

264 For Plasmodium species, subtilisin-like serine protease (SUB1) is a key mediator

265 on site for site-1 protease (AtS1P), a plant subtilisin-like serine protease (subtilase).

266 dress this issue we have concentrated on the subtilisin-like serine protease encoding gene ABNORMAL L

267 and invasion, controlling maturation of the subtilisin-like serine protease SUB1 in exoneme secretor

268 The essential subtilisin-like serine protease SUB1 of Plasmodium meroz

269 ng of proAtPSK4 was dependent on AtSBT1.1, a subtilisin-like serine protease, encoded by one of 56 su

270 Subtilisin-like serine proteases (SBTs) are extracellula

271 rtases (PCs) form a family of nine secretory subtilisin-like serine proteases, seven of which cleave

272 The propeptides of subtilisin-like serine proteinases (subtilases, SBTs) se

273 Instead, a subtilisin-like serine-dependent plant protease named ph

274 convertases (PCs) comprise a large family of subtilisin-like, eukaryotic, serine endoproteases that p

275 Proprotein convertase subtilisin-like/kexin type 9 (PCSK9) is a key regulator

276 PCSK9 (proprotein convertase subtilisin-like/kexin type 9) is an emerging target for

277 (wild type) or PCSK9 (proprotein convertase subtilisin-like/kexin type-9) gain-of-function Ossabaw m

278 Thus, subtilisin might be particularly beneficial for system-w

279 resonance (NMR), revealing that it mimics a subtilisin prodomain including a flexible C-terminal pep

280 The substrate is based on a stabilized subtilisin prodomain, extended across the active site by

281 Below a threshold concentration, subtilisin promotes colony growth and expansion.

282 Purified subtilisin promotes the growth and expansion of P. dendr

283 t the identification and characterization of subtilisin propeptide-like inhibitor 1 (SPI-1) from Arab

284 Gbb and Scw have three functional furin/subtilisin proprotein convertase cleavage sites; two bet

285 that undergo proteolytic processing by furin/subtilisin proprotein convertases to release the active

286 The subtilisin protease (SUB; Clan SB, family S8) of Leishma

287 These allergic responses were dependent on subtilisin protease activity, protease-activated recepto

288 The subtilisin protease TgSUB1 trims several MICs on the par

289 tely 80-kDa passenger domain that contains a subtilisin-related domain.

290 onserved regions in a multigene family of 56 subtilisin-related proteolytic enzymes in Arabidopsis th

291 ed and found to be inactive, but exposure to subtilisin resulted in cleavage to the active, 12 kDa fo

292 vide extensive information for understanding subtilisin's substrate binding and catalytic mechanism,

293 mbined with mathematical modeling, show that subtilisin serves to regulate growth of the colony.

294 Also, subtilisin stimulated the expression of the proallergic

295 well studied endopeptidases belonging to the subtilisin superfamily.

296 at purified StmPr1 behaves more similarly to subtilisin than to trypsin.

297 thways involved in allergic sensitization to subtilisin that potentially contribute to initiate aller

298 our knowledge, the first report of a fungal subtilisin that shows eliciting activity in plants.

299 haFD retained the ability to be activated by subtilisin to 108.8 +/- 20.9 microS, a level not signifi

300 btained by the combination of three enzymes (subtilisin, trypsin and flavourzyme) employed sequential